CA Patent

CA1086715A — Steroids

Assigned to Bristol Myers Squibb Co · Expires 1980-09-30 · 46y expired

What this patent protects

ABSTRACT OF THE DISCLOSURE This specification relates to the production of 9.alpha.-halo-11.beta.-hydroxy-corticosteroids, to intermediates used in the production of such steroids, and to the production of such intermediates themselves. The specification is particularl…

USPTO Abstract

ABSTRACT OF THE DISCLOSURE This specification relates to the production of 9.alpha.-halo-11.beta.-hydroxy-corticosteroids, to intermediates used in the production of such steroids, and to the production of such intermediates themselves. The specification is particularly concerned with the production of such steroids having anti-inflammatory action, e.g. beclomethasone dipro-pionate. There is disclosed a new route for preparing 9.alpha.-halo-11.beta.-hydroxy-corticosteroids which involves the formation of novel 9.beta.,11.beta.-epoxy steroids which themselves may be con-veniently obtained from the corresponding 9.alpha.-bromo-11.beta.-hydroxy-corticosteroids.

Drugs covered by this patent

Patent Metadata

Patent number
CA1086715A
Jurisdiction
CA
Classification
—
Expires
1980-09-30
Drug substance claim
No
Drug product claim
No
Assignee
Bristol Myers Squibb Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.